ALEXANDRIA, Va., Sept. 23 -- United States Patent no. 12,419,848, issued on Sept. 23, was assigned to REMICINE IP B.V. (Velsen-Noord, Netherlands).
"Treatment of hyperinflammatory syndrome" was invented by Djohan Hasan (Kasterlee, Belgium).
According to the abstract* released by the U.S. Patent & Trademark Office: "Described is an antagonist of a mammalian P2X7R for use in the treatment of a hyperinflammatory syndrome in a mammalian patient, by primary lymph node targeted administration of the said P2X7R antagonist in the said patient to a concentration in the said targeted lymph nodes that is above the maximal tolerable plasma level of the said antagonist in the said mammal."
The patent was filed on March 31, 2021, under Application No....